Testing for Non‐Severe Heritable Platelet Function Disorders
International Journal of Laboratory Hematology · 2026-12 · 48 (6) · 1279-1288
DOI: 10.1111/ijlh.70192 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Laboratory Hematology, online erschienen am 03.07.2026. Verfasst von Kate Burley und 3 weiteren Autor:innen. Beteiligte Einrichtung: Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK. Hauptthemen laut MEDLINE: Blood Platelet Disorders, Platelet Function Tests, Blood Platelets. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute for Health and Care Research, Wellcome Trust.
Abstract (Originalsprache)
Heritable platelet function disorders (HPFD) are a diverse group of bleeding disorders characterised by a primary qualitative defect in platelet function rather than platelet number. HPFD may be broadly categorised according to the severity of bleeding, with Glanzmann thrombasthenia and Bernard Soulier syndrome classically considered severe HPFD, with well‐described clinical and laboratory phenotypes. The remaining non‐severe HPFD are less completely characterised and provide additional challenges in diagnosis despite advances in standardising diagnostic approaches for HPFD. Distinguishing patients with non‐severe HPFD from patients who do not have a bleeding disorder may be aided by employing bleeding assessment tools early in patient assessment, although there may be limitations according to patient factors. Distinguishing patients with non‐severe HPFD from those with acquired platelet function disorders and from those with other heritable disorders of haemostasis (including bleeding disorder of unknown cause) requires more sophisticated clinical and laboratory tools, including platelet light transmission aggregometry, secretion and flow cytometry assays, which can categorise many HPFD to the level of the defective platelet pathway and some to the level of an individual protein. The increasing availability of high‐throughput genetic sequencing has made genetic diagnosis possible for some patients with non‐severe HPFD; however, this is limited by difficulties with standardisation of laboratory phenotyping and the challenges of distinguishing pathogenic from benign genetic variation. This review will focus on updates in diagnostic approaches for patients with non‐severe HPFD since the last IJLH education article on this topic in 2014.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
- Department of Haematology, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK.
ORCID-Profile: Sarah K Westbury
Förderung
- National Institute for Health and Care Research
- Wellcome Trust
Zitieren
APA
Burley, K., Cornish, N., Carretero, M. M., & Westbury, S. K. (2026). Testing for Non‐Severe Heritable Platelet Function Disorders. International Journal of Laboratory Hematology, 48(6), 1279-1288. https://doi.org/10.1111/ijlh.70192
Vancouver
Burley K, Cornish N, Carretero MM, Westbury SK. Testing for Non‐Severe Heritable Platelet Function Disorders. International Journal of Laboratory Hematology. 2026;48(6):1279-1288. doi:10.1111/ijlh.70192
BibTeX
@article{Burley2026,
author = {Burley, Kate and Cornish, Naomi and Carretero, Maria Molina and Westbury, Sarah K},
title = {Testing for Non‐Severe Heritable Platelet Function Disorders},
journal = {International Journal of Laboratory Hematology},
year = {2026},
volume = {48},
number = {6},
pages = {1279--1288},
doi = {10.1111/ijlh.70192}
}
EUVIMED